Please try another search
NANO MRNA Co.,Ltd. researches, develops, produces, and sells pharmaceuticals using micellar nanoparticles technology in Japan. The company’s pipeline products include RUNX1 (mRNA) for the treatment in the area of tissue generation and vaccines; and NC-6100 PRDM14 (siRNA), which is in phase I clinical trials for the treatment of breast cancer. Its product pipeline also comprises TUG1 (ASO) for glioblastoma multiforme. In addition, it offers Complex, an antibacterial ear drops; cosmetic raw material, and platelet-rich therapy. The company was formerly known as NanoCarrier Co., Ltd. and changed its name to NANO MRNA Co.,Ltd. in June 2023. NANO MRNA Co.,Ltd. was incorporated in 1996 and is headquartered in Tokyo, Japan.
Name | Age | Since | Title |
---|---|---|---|
Satoru Iino | - | - | Director |
Teruo Okano | 74 | 1996 | Independent External Director |
Satoru Iino | 58 | 2012 | Independent Director |
Shiro Akinaga | 67 | 2020 | President, CEO, CSO, MD of R&D Division and Director |
Koji Fujimoto | 51 | 2019 | CFO, MD of Corporate Division & Director |
Kazunori Kataoka | 73 | 2020 | Independent Director |
Atsushi Matsumura | 61 | 2012 | Executive Chairman of the Board |
Takashi Matsuo | 62 | 2023 | Outside Audit & Supervisory Board Member |
Tetsuhito Matsuyama | 61 | 2015 | Chairman of Standing Audit & Supervisory Board |
Seiichiro Wada | 61 | 2023 | Outside Audit & Supervisory Board Member |
Yuki Hasegawa | 45 | 2021 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review